#nicholslab
@nicholslab1
Followers
2K
Following
8K
Media
65
Statuses
1K
Professor, Western University Chief, Head and Neck Surgical Oncology Translational Scientist https://t.co/M4lTrD9DDg Microvascular Surgery Fellowship Director
London, Ontario
Joined January 2018
So so proud of this incredible Canadian AIrways Research (CARE) group collaboration @RJLin @peteryufanzeng ! 🙌🏽🙌🏽🙌🏽So much exciting iSGS research to come! @WesternOtoHNS @UnityHealthTO @UofT_OHNS.
1/🚨 Proud to share TWO back-to-back papers unraveling the pathogenesis of idiopathic subglottic stenosis (iSGS) using multi-omics approaches published today @eBioMedicine @nicholslab1 @RJunLinMD as part of the Canadian Airways Research Group .Let's break it down🧵👇 #MedTwitter
1
1
9
RT @peteryufanzeng: 🚨 New #preprint alert! 🚨 Very proud to share our latest work unraveling treatment resistance mechanisms in anaplastic….
0
6
0
RT @peteryufanzeng: A true pleasure to present our latest work on subglottic stenoses at #APSR24 in the beautiful HK 😍 Stay tuned for more….
0
1
0
Plot twist! The 5 year minimum follow up results of the ORATOR trial show that the MDADI curves converge mainly due to a decline in the CRT/RT arm at 5 years (later toxicity kicking in?!?) . Despite the title of the paper we are reconsenting patients to obtain 10 year follow up.
1
15
39
RT @LylesNoah: I have Asthma, allergies, dyslexia, ADD, anxiety, and Depression. But I will tell you that what you have does not define wh….
0
37K
0
RT @Western_MDPhD: Last month our incredible student @peteryufanzeng defended his PhD. Congratulations Dr. Zeng! We hope you are enjoying y….
0
1
0
RT @CJTsaiMDPhD: ‼️🚨Happening now - HN oral abstracts #ASCO24 .Much anticipated Ph3 IMPT vs IMRT for OPC presented by @SJFrankMD @MDAnderso….
0
9
0
RT @CJTsaiMDPhD: 🚨📢Happening now - HN oral abstracts #ASCO24‼️. PRACTICE CHANGING trial of hypoxia directed major radiation de-escalation a….
0
80
0
RT @peteryufanzeng: Our GATCI anaplastic thyroid cancer genomic dataset can now be accessed at @cbioportal .We hope….
0
2
0
RT @peteryufanzeng: I will be defending my #PhD thesis in 2 weeks. Please DM me for Zoom link if interested.
0
7
0
Thrilled to be working with @DropletBiosci and @DrCorreaRO head and neck cancer research projects!! @WesternOtoHNS @SchulichMedDent.
Welcome @LHSCCanada to the @DropletBiosci team! This marks an exciting opportunity for us to collaborate with @nicholslab1, @DrCorreaRO, Dr. Rahul Nayak, @DrDanBreadner, and their colleagues to advance patient care.
1
3
16
RT @WesternOtoHNS: Dr. Hussain Alsaffar joined us from Riyadh, Saudi Arabia as our distinguished guest alumnus, sharing thoughts on resilie….
0
1
0
RT @DrJohndeAlmeida: Thrilled to get this published. The FIND trial demonstrates the ability to reduce radiotherapy volumes after TORS for….
pubmed.ncbi.nlm.nih.gov
ClinicalTrials.gov Identifier: NCT03281499.
0
15
0
RT @Western_MDPhD: Inspired and encouraged following the @CSCI_SCRC @CITAC_ACCFC annual joint meeting in Vancouver attended by several @Sch….
0
3
0
Congratulations to @peteryufanzeng for his oral presentation award at the @CITAC_ACCFC conference for his work on anaplastic thyroid cancer genomics and targeted therapy! .@Western_MDPhD @SchulichMedDent @WesternOtoHNS @LHSFCanada @LHSCCanada @CIHR_ICR
0
0
16
RT @peteryufanzeng: Had a blast presenting our work on mechanisms of resistance to RAF inhibition in lethal thyroid cancers at #AACR24 .Sta….
0
3
0
MD PhD student @peteryufanzeng and Post Doc @mushfiqddc presenting our latest work in targeted therapy for anaplastic thyroid cancer and a novel immmunotherapy combination for HNSCC at #AACR24 @AACR @Western_MDPhD @SchulichMedDent @LHSFCanada @CIHR_ICR
0
2
20
Unfortunately many patients progressed while waiting for the Tumorgraft results, however a subset of patients derived benefit. Another drawback is that we could not test immunotherapy in these immunocompetent models.
0
0
1
Some studies are massive efforts that don’t work out the way you hope! We worked with @ChampionsOncol1 to attempt use personalized Tumorgrafts (TM) to guide the choice of chemotherapy in RMHNSCC. Punch line 🥊 it’s hard!.
cureus.com
Recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) is associated with a poor prognosis and short survival duration. There is an urgent need to identify personalized predicto...
1
0
13